ACRV
Acrivon Therapeutics, Inc. Common Stock
NASDAQ · Healthcare · Biotechnology · US
$2.13
+3.40%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.0x
Market Cap
$91.28M
MomentumView details →
1D Return
+3.40%
YTD Return
−13.07%
RSI (14)
56.2
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.0x
Market Cap
$91.28M
RSI (14)
56.2
MomentumView details →
1D Return
+3.40%
YTD Return
−13.07%
SummaryUpdated Jun 1, 2026
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in Watertown, Massachusetts. The company went public in November 2022 and focuses on developing precision oncology medicines using its proprietary proteomics-based platform to identify patients most likely to respond to specific cancer treatments. Acrivon operates in the competitive biotechnology sector, specifically targeting DNA damage response pathways in cancer cells.
Similar companies
Latest newsMore news →
No recent news for ACRV.